肺腺癌化疗方案及辅助药物使用分析  

Analysis of Chemotherapeutic Regimens and the Use of Adjuvant Chemotherapeutic Drugs in Lung Adenocarcinama

作　　者：许金华[1] 朱文玉[1] 

机构地区：[1]南京胸科医院药学部,南京210029

出　　处：《中国药房》2013年第22期2038-2040,共3页China Pharmacy

摘　　要：目的:对我院住院肺腺癌患者的化疗方案及辅助药物的使用情况进行调查分析,为该类患者的药物治疗监控与评析提供依据。方法:收集2011年在我院住院化疗的肺腺癌患者共86例,提取其医嘱中化疗药、辅助治疗药的名称、用法用量、起止时间、溶媒选择,对照相关治疗指南和药品说明书对化疗方案、止吐方案及辅助治疗药使用的合理性进行评价。结果:第3代化疗药与铂类联合的化疗方案占82.73%;在止吐、保肝等辅助治疗中,合并用药较多,使用时间较长,存在超适应证用药现象。结论:我院对住院肺腺癌患者的化疗方案选择是合理的,但辅助治疗尤其是止吐方案未能按止吐风险分级选择药物,需要进一步加强监管。OBJECTIVE： To investigate the chemotherapeutic regimens and the use of adjuvant chemotherapeutic drugs in lung adenocarcinoma patients of our hospital, and to provide reference for drug therapy monitoring and evaluation in the patients. METH- ODS： 86 patients with lung adenocarcinoma receiving chemotherapy were collected from our hospital in 2011. Rationality of chemo- therapeutic regimens, preventing chemotherapy-induced vomiting and use of adjuvant chemotherapeutic drugs were evaluated by ex- tracting chemotherapy drugs, name of adjuvant chemotherapeutic drugs, dosage and usage, time of emergence and end, solvent se- lection, and controlling related guidance and package inserts. RESULTS： 82.73% of chemotherapeutic regimens were the combina- tion of third generation chemotherapeutic drugs with platinum. In adjunctive therapy, such as antiemetic therapy and liver protec- tion, there were more combination, long course of treatment and off-indications drug use. CONCLUSIONS： Chemotherapy regi- men for lung adenocarcinoma inpatients is reasonable, but the supervision and management of adjunctive therapy needs to be strengthened, especially drug selection of antiemetic regimen is not in line with the antiemetic risk classification.

关 键 词：肺腺癌 化疗方案 辅助化疗药 分析 

分 类 号：R969.3[医药卫生—药理学] R287[医药卫生—药学]